Search
Bausch + Lomb Corp
BLCOAdd to Watchlist
16.540USD
-0.090-0.54%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
5.86BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.54%
5 Days
+10.78%
1 Month
+5.69%
6 Months
-3.56%
Year to Date
-3.16%
1 Year
+33.39%
Key Figures
16.620Open
16.660High
394.40KVolume
LossP/E TTM
14.83P/E Dynamic
--Dividend TTM
0.11%Turnover Ratio
16.630Prev. Close
16.320Low
3.73MTurnover
LossP/E Static
0.91P/B
0.00%Div Yield TTM
-1.55%ROA
18.91552wk High
1.11Volume Ratio
-317.00MNet Profit
354.21MShares
-0.6165EPS TTM
0.58Beta
-3.44%ROE
11.22052wk Low
2.04%Amplitude
56.59%Gross Margin
5.86BMarket Cap
4.18Reward/Risk
1.93%Risk Rate
TradingKey Stock Score of Bausch + Lomb Corp
Currency: USD Updated: 2026-06-29Key Insights
Bausch + Lomb Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 18.09.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bausch + Lomb Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Bausch + Lomb Corp Highlights
StrengthsRisks
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.03% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.10B.
Undervalued
The company’s latest PE is -26.97, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.30M shares, decreasing 38.29% quarter-over-quarter.
Held by Larry Robbins
Star Investor Larry Robbins holds 1.93M shares of this stock.
Analyst Rating
Based on
12
analysts
Hold
Current Rating
18.091
Target Price
+10.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bausch + Lomb Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bausch + Lomb Corp Info
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Ticker SymbolBLCO
CompanyBausch + Lomb Corp
CEOSaunders (Brenton L)
Websitehttps://ir.bausch.com/
Related Instruments
-1.10%
-1.12%
-2.20%
-2.04%
-1.28%
-0.15%
-4.84%
-3.35%
-0.64%
-0.36%
-1.11%
-1.86%
+0.49%
-0.86%
+2.15%
-1.77%
-2.57%
-0.32%
-0.03%
-0.43%Popular Instruments
52235.000
+81.800 (+0.16%)
30218.400
+510.700 (+1.72%)
7482.000
+49.800 (+0.67%)
15596.000
+145.000 (+0.94%)
70929.000
+455.000 (+0.65%)
6326.700
+70.900 (+1.13%)
69.941
-0.375 (-0.53%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4011.030
-4.560 (-0.11%)
FAQs
What is the current price of Bausch + Lomb Corp (BLCO)?
The current price of Bausch + Lomb Corp (BLCO) is 16.64.
What is the symbol of Bausch + Lomb Corp?
The ticker symbol of Bausch + Lomb Corp is BLCO.
What is the 52-week high of Bausch + Lomb Corp?
The 52-week high of Bausch + Lomb Corp is 18.91.
What is the 52-week low of Bausch + Lomb Corp?
The 52-week low of Bausch + Lomb Corp is 11.22.
What is the market capitalization of Bausch + Lomb Corp?
The market capitalization of Bausch + Lomb Corp is 5.94B.
Is Bausch + Lomb Corp (BLCO) currently rated as Buy, Hold, or Sell?
According to analysts, Bausch + Lomb Corp (BLCO) has an overall rating of signal_hold, with a price target of 18.09.
What is the Earnings Per Share (EPS TTM) of Bausch + Lomb Corp (BLCO)?
The Earnings Per Share (EPS TTM) of Bausch + Lomb Corp (BLCO) is -1.02.
